NVO
NVO
US6701002056
Novo Nordisk A/S
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 70/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±39.0% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).

Beta (Market Relation)
0.38x
Defensive
Volatility (5Y p.a.)
39.0% p.a.
5-Year Horizon
Max Drawdown (5Y)
-76.0%
5-Year Horizon
Sharpe Ratio
-0.19
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -36%
3 Years 43.2% -76.0% -0.65 -25.4%
5 Years 39.0% -76.0% -0.19 -4.9%
10 Years 32.8% -76.0% 0.12 +6.5%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Elevated Short-Term Volatility: 3Y volatility (43.2%) is noticeably higher than the 5Y average (39.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (39.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -76.0% in the extended horizon.
ende